« Back
Home /
Cabazitaxel

Cabazitaxel

Item no.	S3022-1000
Manufacturer	Selleckchem
CASRN	183133-96-2
Amount	1 g
Quantity options	10 mg 100 mg 1 g 10 g 10 mM/1 mL 200 mg 5 mg 5 g
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Brain Cancer
Type	Inhibitors
Specific against	other
Smiles	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	XRP6258,RPR-116258A,TXD 258,Taxoid XRP6258
Similar products	Cabazitaxel
Available
Storage Conditions	2 years -80 in solvent
Molecular Weight	835, 93
Animal Models	Murine tumor xenografts (colon C38 and pancreas P03)
Clinical Trials	Cabazitaxel has entered in a phase I clinical trial in the treatment of solid cancer.
In vitro	Cabazitaxel increases CYP3A enzyme activities in rat hepatocytes. The mean ex-vivo human plasma protein binding of Cabazitaxel is 91.6%. Cabazitaxel is rapidly and extensively metabolised in numerous metabolites. Cabazitaxel demonstrates activity in several murine and human resistant cell lines. [1] With a 4-day exposure to cabazitaxel, cytotoxicity is noted with relatively low cabazitaxel concentrations. Cabazitaxel shows high antitumor activity in 3 human colorectal cell lines (HCT-116, HCT-8, and HT-29). [2]
In vivo	In accompanying models, Cabazitaxel is noted to have significant antitumor activity. In murine tumor xenografts (colon C38 and pancreas P03), Cabazitaxel elicites complete tumor regressions. Using SF-295 and U251 human glioblastoma cell lines, both orthotopic and subcutaneous murine xenografts are generated. Cabazitaxel treatment leads to complete regression in the majority of subcutaneously implanted tumors. Furthermore, in orthotopic models, Cabazitaxel leads to complete tumor regression in 4 out of 10 U251 tumors. [2]
Solubility (25C)	DMSO 100 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Information	Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide. Cabazitaxel induces autophagy via the PI3K/Akt/mTOR pathway.
Chemical Name	Benzenepropanoic acid, -[[(1, 1-dimethylethoxy)carbonyl]amino]--hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-11-hydroxy-4, 6-dimethoxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, (R, S)-
Features	Cabazitaxel is a semi-synthetic derivative of a natural taxoid.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S3022-1000-datasheet.pdf

S3022-1000-safety-datasheet.pdf